Vertaling van "there being a risk " (Nederlands → Frans) :

TERMINOLOGIE

controle van zwangerschap met verhoogd risico [high-risk]
Surveillance d'une grossesse à haut risque

IN-CONTEXT TRANSLATIONS

Manual for school professionals Moreover, in addition to the team set up by the province of Liège, there is a manual entitled “Le risque suicidaire et les adolescents – Quelques répères pour les directeurs et enseignants du secondaire face à une problématique complexe” (“The risk of suicide and teenagers – some information for secondary school authorities and teachers faced with a complex issue”), which was published in 2001.
Par ailleurs et complémentairement à l’équipe mise en place par la Province de Liège, un guide intitulé « Le risque suicidaire et les adolescents – Quelques repères pour les directeurs et enseignants du secondaire face à une problématique complexe » a été publié en 2001.

With even less input about the callers available than is the case for telephone conversations (there is no way of either seeing or hearing them), the emotional distance between the two persons concerned is even greater and the risk of misunderstanding higher.
Comme on a encore moins d’input sur l’appelant que par téléphone (on ne peut ni le voir ni l’entendre), la distance entre les deux personnes est plus grande sur le plan sentimental et la possibilité de mauvaises interprétations est plus grande.

There is a risk that dealing with access to means might only affect the external causes involved in committing the act, without taking into account the other factors.
Des actions au niveau de l’accessibilité aux moyens risquent de n’agir que sur les causes externes de passage à l’acte sans prendre en compte les autres facteurs.

Therefore, not including tiredness as one of the symptoms to be looked for during the diagnosis could result in there being a risk of failing to recognise the depression.
Il pourrait donc y avoir un risque de non-reconnaissance de la dépression si la fatigue ne fait pas partie des symptômes recherchés lors du diagnostic.

It is these organisations’ experience that these students are not sufficiently aware of how sensitive this topic really is. More precisely, there may be high-risk students in the classroom (i.e. young students with a history of suicidal behaviour or a depression, students who have lost a close relative through suicide…) who will be put in a very difficult position if this topic is broached in an abrupt or ill-considered manner.
Il se peut notamment qu’il y ait des élèves à risque dans la classe (des jeunes avec un comportement suicidaire antérieur, avec une dépression, des élèves qui ont perdu un proche par suicide…) qui auront très difficile si ce thème est abordé en classe de façon imprévoyante et non réfléchie.

There is a risk that a depression is put down to the mourning process and is thus not recognised as such.
Le risque existe qu’une dépression soit attribuée à un travail de deuil et n’est donc pas reconnue.

This release contains forward-looking information about a potential joint venture between Pfizer and Zhejiang Hisun Pharmaceuticals (Hisun) including, among other things, the anticipated benefits there of, that involves substantial risks and uncertainties.
This information contained in this release is as of June 2, 2011, Pfizer assumes no obligation to update forward-looking statements contaiTned in this release as the result of new information or future events or developments. This release contains forward-looking information about a potential joint venture between Pfizer and Zhejiang Hisun Pharmaceuticals (Hisun) including, among other things, the anticipated benefits there of, that involves substantial risks and uncertainties.

In the above-mentioned recent advisory report of the German Federal Institute for Risk Assessment (BfR, 2008) concerning energy drinks and caffeine in particular, there was an explicit re-evaluation of the potential consequences of consuming beverages containing up to 320 mg/litre of caffeine, 4 000 mg/litre of taurine and 2 400 mg/litre of D-glucuronolactone. It continues to express its reservations on this subject and makes the following recommendations:
Par rapport aux boissons énergisantes et à la caféine en particulier, l’avis récent de l’Institut fédéral allemand d’évaluation des risques (BfR, 2008), évoqué plus haut, indique avoir explicitement réévalué les risques potentiels consécutifs à l’ingestion de boissons contenant au maximum 320 mg/l de caféine, 4.000 mg/l de taurine et 2.400 mg/l de D-glucuronolactone et continue à manifester des réserves à leur égard tout en émettant les recommandations suivantes:

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

This release contains forward-looking information that involves substantial risks and uncertainties concerning the possibility of future dividend increases. Such risks and uncertainties include, among other things, the Company’s future financial performance as well as general economic, political, business, industry, regulatory and market conditions.
Such risks and uncertainties include, among other things, the Company’s future financial performance as well as general economic, political, business, industry, regulatory and market conditions.